mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin has been researched along with paraquat in 2 studies
| Studies (mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin) | Trials (mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin) | Recent Studies (post-2010) (mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin) | Studies (paraquat) | Trials (paraquat) | Recent Studies (post-2010) (paraquat) |
|---|---|---|---|---|---|
| 69 | 0 | 42 | 5,741 | 25 | 1,991 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dixit, A; Mishra, M; Prakash, O; Singh, MP; Singh, PK; Srivastava, G; Verma, D | 1 |
| Dong, X; Song, C; Sun, D; Wang, R; Xu, Y | 1 |
2 other study(ies) available for mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin and paraquat
| Article | Year |
|---|---|
Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Homeodomain Proteins; Levodopa; Male; Maneb; Metalloporphyrins; Mice; Microglia; Minocycline; Mitochondria; Paraquat; Parkinson Disease, Secondary; Proteome; Stathmin; Superoxide Dismutase | 2013 |
MnTMPyP inhibits paraquat-induced pulmonary epithelial-like cell injury by inhibiting oxidative stress.
Topics: A549 Cells; Acute Lung Injury; Apoptosis; Calcium; Caspase 3; Cell Survival; Endoplasmic Reticulum Chaperone BiP; Epithelial Cells; Glutathione Reductase; Humans; Membrane Potential, Mitochondrial; Metalloporphyrins; Oxidative Stress; Paraquat; Pulmonary Alveoli; Reactive Oxygen Species | 2018 |